SavedAdd your journal

Journals / Erciyes Medical Journal / 2018 / Cilt: 40 - Sayı: 2

In vitro Susceptibilities of Linezolid and Tigecycline against Drug-Resistant Mycobacterium tuberculosis Isolates

Güneş ŞENOL
Şevket DERELİ
Gülsüm ARI
Meral COŞKUN
Can BİÇMEN
Osman KAFTAN
AHMET EMİN ERBAYCU
Pages
61–64
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Treatment of DR-TB with TGC is not promising according to study results.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely difficult, and there is a need for new and effective drugs.
📊
Key Findings & Data:Results: A total of 26 strains resistant to any drug against M. tuberculosis were tested.
💡
Conclusion & Impact:Treatment of DR-TB with TGC is not promising according to study results.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: The treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely difficult, and there is a need for new and effective drugs. The aim of this study was to determine the minimum inhibitory concentration (MIC) of linezolid (LZD) and tigecycline (TGC) against DR Mycobacterium tuberculosis isolates. Materials and Methods: The study was conducted at a referral chest diseases and chest surgery hospital. Isolates were obtained from consecutive patients. Susceptibilities to LZD and TGC were studied using the agar dilution method. Results: A total of 26 strains resistant to any drug against M. tuberculosis were tested. Ten isolates (38.5%) had an MDR pattern. MIC50 and MIC90 values of LZD were detected to be 0.05 and 1 µg/mL, respectively. Among all isolates, 96% M. tuberculosis strains were found to be susceptible to LZD. An approved breakpoint for TGC does not exist. MIC50 and MIC90 values of TGC were found to be 16 and 64 µg/mL, respectively. Conclusion: LZD seems to be a good alternative for treatment of DR-TB. However, TGC showed high MIC values. Treatment of DR-TB with TGC is not promising according to study results.

🔖

Cite This Article

ŞENOL, G., DERELİ, Ş., ARI, G., COŞKUN, M., BİÇMEN, C., KAFTAN, O., ERBAYCU, A. E. (2018). In vitro Susceptibilities of Linezolid and Tigecycline against Drug-Resistant Mycobacterium tuberculosis Isolates. Erciyes Medical Journal, Cilt: 40 - Sayı: 2, 61–64. https://ajindex.com/articles/223470

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. World Health Organization. WHO tuberculosis fact sheet, 2016. World Health Organization. Global tuberculosis report 2015: WHO report 2015/WHO/HTM/TB/2015.22. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis, 5th ed, 2015. WHO/HTM/TB/2015.13. Gualano G, Capone S, Matteelli A, Palmieri F. New antituberculosis drugs:from clinical trial to programmatic use. Infect Dis Rep 2016
  2. 8(2): 65-9. [CrossRef] Alcala L, Ruiz-Serrano M, Turegano C, García De Viedma D, DíazInfantes A, Marín-Arriaza M, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line anti-tuberculous drugs. Antimicrob Agents Chemother 2003
  3. 47(1): 416–7. [CrossRef] Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Pelaquin CA, et al. Early and extended early bacterial activity of linezolid in pulmonary TB. Am J Respir Crit Care Med 2008
  4. 178(9): 1180-5. [CrossRef] Ford C, Hamel J, Stapert D, Moerman JK, Hutchinson DK, Barbachyn MR, et al. Oxazolidinones: new antibacterial agents. Trends Microbiol 1997
  5. 5(5): 196-200. [CrossRef] Baietto L, Corcione S, Pacini G, Perri GD, D’Avolio A, De Rosa FG. A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? Curr Drug Metab 2014
  6. 15(6): 581-98. [CrossRef] Coban AY, Deveci A, Tanriverdi Cayci Y, Uzun M, Akgunes A, Durupinar B. In vitro effect of tigecycline against Mycobacterium tuberculosis and a review of the available drugs for tuberculosis. African Journal of Microbiology Research 2011
  7. 5(3): 311-15. CLSI M24-A2, 2011. Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes
  8. Approved Standard, M24A2E. Clinical and Laboratory Standards Institute, 2012. Methods for dilution antimicrobial susceptibility testing for bacteria that grows aerobically. Approved standard M7-A9, Clinical and Laboratory Standards Institute, Wayne, PA. Hoşgor Limoncu M, Ermertcan S, Erac B, Taşlı H. An investigation of the antimicrobial impact of drug combinations against Mycobacterium tuberculosis strains. Turk J Med Sci 2011
  9. 41(4): 719-24. Guidelines for the programmatic management of drug-resistant tuberculosis — 2011 update. Geneva: World Health Organization, 2011 (WHO/HTM/TB/2011.6). Lee M, Lee J, Carroll M, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis N Engl J Med 2012
  10. 367(16): 1508-18. [CrossRef] Jaramillo E, Weyer K, Ravigl